
Rezolute (RZLT) Stock Forecast & Price Target
Rezolute (RZLT) Analyst Ratings
Bulls say
Rezolute is a promising biopharmaceutical company with a positive outlook due to its focus on rare and metabolic diseases and its strong pipeline. Despite recent negative results from the sunRIZE study, the company has multiple ongoing trials and collaborations, and its cash position allows for continued development. With Breakthrough Therapy Designation and potential for accelerated approval, Rezolute has the potential to bring needed therapies to patients and create value for shareholders in the future.
Bears say
Rezolute is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases, such as congenital hyperinsulinism. However, a placebo effect may have contributed to the failure of its phase 3 trial for its lead candidate, RZ358. Limited data on standard of care and a small sample size also raise concerns about the drug's potential efficacy and safety. Additionally, as a clinical-stage company, Rezolute faces various risks that could impact its timeline for product development and regulatory approvals.
This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares